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How to obtain solid and ethical evidence
Introduction
One definition of the practice of evidence-based medi-
cine (EBM) has described it as “the practice of medicine
which eliminates the use of expensive, ineffective or
dangerous decision making.”1 This means that the
clinician has to critically appraise and apply current
evidence in clinical practice.2 The paradigm of decision
making under EBM ensures that effective care of
the individual occurs. There is no doubt that EBM is
essential in this era of information technology. Histori-
cally, the development of EBM has paralleled the
sophistication of clinical trials methodologies. Many
would agree that advances in clinical trials methods
lead to the development of the concept of evidence-
based medical practice.3 The development of pro-
gressively more rigorous clinical trial methods has
generated more controlled and better quality data on
which to base the clinical management of patients.
However, it is also increasingly more evident that the
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daily practice of medicine is not always in line with
the results of contemporary quality clinical studies.
There are usually two ways for clinicians to obtain
properly controlled clinical data—from clinical trials
and surveillance studies. The importance of clinical
trials as regards the development of medicine cannot
be stressed too strongly.1-6 This is reflected by the many
articles in clinical journals that are related to clinical
trials. For example in 1997, about 40% of the original
articles published in the Lancet described results of
clinical trials. Investigators used to perform clinical
trials in their own way because there were no ‘guide-
lines’. Whereas the purists wish to obtain absolute
evidence from human experimentation, the moralists
wish to perform no trials at all as all patients should
receive the best treatment.7 Both of these extreme views
are illogical and against EBM principles. A sensible
compromise is to obtain the best possible evidence
within ethical constraints. Many reader-friendly books
and articles discuss methods by which medical and
scientific information can be found and then translated
into everyday clinical practice.3-6 Unfortunately, the
methods needed to extract solid and ethical evidence
are usually only described in statistically-oriented
textbooks that are often inaccessible and incompre-
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hensible to many busy clinicians.8-11 This short article
has been written with the aim of bridging this gap
for general readers. The techniques and theories on
performing surveillance studies are largely epidemio-
logical and will not be described here.
Why do clinical trials?
A clinical trial is a study of the action of a therapeutic
or diagnostic intervention with a drug, device, or health
care product in human subjects. As the untreated state
of most diseases displays some longitudinal variation,
the mere observation of a ‘clinical improvement’ does
not necessarily imply a beneficial effect due to a drug
or treatment protocol. Several confounding factors are
present, many of which are unknown, which could
affect the results of a trial. The different stages in the
development of a drug and the associated clinical trials
are shown in Box 1.
The aims of a therapeutic trial must be clearly defined
and generally encompass one or more of the following:
whether or not a treatment is effective; the efficacy of a
treatment (with or without comparison with other modes
of therapy); the identification of which patient subgroup
is likely to respond; administration details such as the
optimum route and dosage; and monitoring of any adverse
reaction.
Good clinical practice and the International
Conference on Harmonization guidelines
The gold standard clinical study, particularly thera-
peutic or interventional, is undoubtedly the ‘prospec-
tive, randomised, double-blind and placebo-controlled
study with data monitoring and preceding sample size
calculation’. All good clinical studies should comply
with the principles of good clinical practice (GCP) that
were published in 1996 in the International Conference
on Harmonization (ICH) technical requirements for the
registration of new drugs. Unless these guidelines are
observed, the results of a drug trial could be viewed as
‘invalid’ as far as registration of a new drug is concerned.8
The GCP guidelines are a set of management pro-
cedures designed to prevent mistakes and malpractice
and to protect research subjects; GCP sets the standards
for the ethical evaluation of clinical research with the
aim of securing the safety and rights of trial participants.
In addition, GCP outlines the activities, from the
planning to concluding stages, of the investigators and/
or sponsor, and monitors the trial to ensure that the
data and the reported results are credible, accurate, and
useful.12-14
The ICH technical requirement for the registration
of pharmaceuticals for human use has produced a
set of guidelines on GCP. The guidelines have taken
into consideration the usual practices in the United
States, the European Union, Japan, and Canada, and
must be followed whenever possible. Although the
guidelines were well publicised,12-14 a recent local study
has conclusively shown a lack of such knowledge
among clinicians and pharmaceutical personnel.15
Study design
Poor study design leads to the generation of poor-
quality data, which means that trial patients undergo
risks unnecessarily, resources are spent unjustifiably,
and investigators’ energy and time are wasted. All
clinical trials must have a fairly lengthy written protocol
and this should remain as the ‘map’ throughout the
study. The design of a study should contain details of
the aims, the rationale for the design, the inclusion and
exclusion criteria used for patient recruitment, the
Box 1. The various stages of clinical trials
Phase Features
I Clinical pharmacology (20-50 subjects)
Usually healthy or occasionally patient volunteers
Pharmacokinetic determination (absorption, distribution, metabolism, excretion, etc)
Pharmacodynamics (biological effects) investigated
Safety profiles
II Clinical investigation (50-300 subjects)
Targeted patient group
Pharmacokinetics, pharmacodynamics, and dose-finding investigated
III Therapeutic trials (>250 subjects)
Efficacy and safety studies with or without comparison with established treatment
IV Postmarketing surveillance (>2000 subjects)
Long-term safety and efficacy surveillance
Efficacy comparison studies
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withdrawal procedures for patients, the statistical basis
of the study, and give details about the investigator.16
The background to a study
Consultation with leading experts (eg through collabo-
ration or attendance at international scientific meetings)
and a critical review of the literature may help identify
‘gaps’ in the current knowledge.3-6 All researchers are
human and have limited expertise, time, resources, and
energy. The design of a prospective study should there-
fore be sensibly restricted to address ‘gaps’ in the
knowledge that interest the researcher. In this way, the
most scientifically and clinically worthy results can
be expected, which will be collected enthusiastically
by the researcher.
Need for a control group
As disease activity fluctuates in most diseases, whether
or not the patient is receiving efficacious treatment,
overt improvement or deterioration after the initiation
of a new treatment in a clinical trial does not always
indicate efficacy or a deleterious effects.17 The temp-
tation to give the ‘new’ treatment to all the patients,
thereby ‘saving’ time, energy, and resources must be
resisted. The need for a comparable and parallel control
group is present in most, if not all, clinical trials.17 This
will reassure the investigators that the results (benefits
or otherwise) observed in the treated patients are
more likely to be specifically related to the treatment
itself rather than a mere reflection of changes in the
environment, diagnostic standards, concurrent dis-
eases, or other unexpected confounding factors,
including the formidable placebo effect.18 Recruitment
of a comparable control group is best done by the
randomisation process in a double-blind study.
The need for prospective data
The use of historical information obtained for the same
or other patients to provide control data (ie the use of
historical controls) is a common practice that can lead to
the generation of poor quality conclusions.19 Data from
the same patient group may vary tremendously over time,
even in those with chronic diseases. The use of a non-
concurrent control group may therefore introduce a
huge bias, due to a difference in environmental, non-
medicinal, or various other variables that a researcher
cannot account for. It is therefore best to start with
prospective studies when the data can be collected in
parallel from the control and test groups by the researcher.
Construction of a protocol
A protocol should be written to satisfy the following
requirements9,16: the study must be ethical and provide
for the protection of the rights of the subjects; the study
parameters should be sufficiently sensitive; adequate
measures must be included to determine the safety of the
drug; the study design must be scientifically sound and
acceptable to the investigators; the protocol must meet
all legal and regulatory requirements; and the number of
patients involved in the study must be stated and justified.
The writing of a protocol is complex and beyond the scope
of this short article. However, the components of a
standard protocol are outlined in Box 2.
Definition of outcome parameters
The literature review and expert consultation should
yield some information on the gaps in the literature
and also likely parameters that are meaningful both
clinically and scientifically. These parameters must
also be sufficiently sensitive (ie measurable) and their
Box 2. Components of a standard protocol
(1) Standard cover page: title, date, protocol number, test medicine, form, regulatory status, name, address,
telephone numbers of the sponsor
(2) Background: brief description of the scientific and clinical data
(3) Objectives of the study: definition of the primary endpoint
(4) Recruitment criteria
(5) Study design: eg double-blind, placebo-controlled, randomised
(6) Drug treatment plans: form, strength, timing, duration, labelling and storage conditions, etc
(7) Parameters assessed: primary and secondary efficacy measurements
(8) Flow chart of the study logistics
(9) Adverse drug events: define ‘serious’ and report out-of-hours problems
(10) Name of the Ethics Committee
(11) Description of the consent process with reference made to the Helsinki Declaration, 1964
(12) Statistical information: sample size, analysis plan, etc
(13) Data management plans: especially if a contract research organisation is engaged
(14) Auditing procedures: state frequency and methods
(15) Declaration of insurance
(16) Criteria for termination of study: including completion of recruitment, reasons for pre-mature termination, etc
(17) Appendices usually include: the consent form, references to investigative procedures, and a copy of the
Helsinki Declaration, etc
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measurement feasible within the capability of the
investigators. Definitions of the primary and secondary
outcome measures must be made to help focus the
research. Indiscriminate collection of numerous para-
meters, irrespective of clinical or scientific justification,
is sometimes done just to ensure that a ‘positive’ result
is generated by a study. This is both unethical and
scientifically unsound, and predisposes to the ‘discovery’
and subsequent reporting of a ‘chance finding’.20,21
Elimination of data bias
Bias can be introduced at various stages of a study
that will compromise the analysis and interpretation
of data. The most important feature in the design
of a clinical trial is the elimination of any possible
known bias. Bias can occur in many ways at various
stages.8-11 The literature review process has an intrinsic
publication bias as positive results are likely to be
published in more prestigious journals and therefore
be read by fellow researchers. This might artificially
enhance the effects of a certain treatment as any failures
are less frequently reported or only reported in less
prestigious journals. The selection of patients is also
important as a selection bias will result in invalid
comparisons being made between the control and test
groups. Investigators could also bias a study through
improper execution of the experimental procedures.
Measurement of outcome can also be biased as some
investigators tend to ignore the unwelcome results,
particularly minor to moderate adverse reactions to a
test drug. Data interpretation can also be severely
biased if the researcher is keen to produce ‘positive’
results that will help achieve publication of the work
in journals.
A prospective, double-blind study whereby patients
are randomly recruited using the same stringent
inclusion and exclusion criteria has the greatest
probability of reducing bias in recruitment, execution
of procedures, and outcome assessment. Asking the
statistician to perform analysis without knowing the
treatment received in the trial also eliminates some bias,
although the principal investigator bears the final
responsibility of interpreting the results fairly and
correctly in a logical and scientific manner.8-11
Recruitment of subjects
The criteria used for subject recruitment must be
defined before the study commences and then followed
rigidly. Any subsequent alteration must be resisted
and must be agreed on by the principal investigator,
sponsor, and ethics committee. Inclusion criteria generally
include the age range, gender, disease diagnostic
criteria, and disease severity markers for the pro-
spective patients. The severity markers generally also
constitute the parameters to be measured in the
study and it is of utmost importance to define these
quantitatively wherever possible. Exclusion criteria
must also be carefully laid down. These generally
include known adverse reaction(s) to the test treatment,
consideration of child-bearing potential for most drugs
with the remotest teratogenic potentials, concomitant
conditions, and disease-specific criteria.8-11, 22-24
The randomised recruitment of patients, sometimes
regarded as inconvenient by many investigators, is one
of the most important ways of eliminating selection
bias, particularly when combined with a double-blind
design.25 The randomisation process can be simple,
block, or systematic block in design. Simple rando-
misation entails the assignment of treatment (equivalent
to tossing a coin) and is the most elementary and
commonly practised method. Unequal allocation can
result, however, particularly if the sample size is small,
making subsequent analysis very difficult. Block
randomisation using a fixed treatment sequence (eg
ABAABBBA for a ‘block’ of eight patients receiving
treatment arms A or B) is more advanced and con-
venient enough for mostly clinical research practice.
Systematic block randomisation assigns a patient to a
treatment based on a random order in the first block,
which is then repeated in all subsequent blocks.16,25
Written informed consent, in the subject’s native
language, must be obtained in all clinical therapeutic
studies.26 The first portion of the consent form generally
describes the study and nature of the subject’s involve-
ment while the second part is where the subject should
sign. The principal investigator and a witness should
also sign the form stating that the investigator has
explained in full the nature of the study to the subject.
As the first part of the study describes the aims, stages,
procedures involved, and possible adverse reactions
from the test treatment, it is standard practice in the
West to issue a copy for the patient to keep, although
this practice is not yet common locally.
Elimination of intra- and inter-observer errors
Biological data are usually not perfect and errors can
arise in the following situations: by sampling the wrong
group (ie one atypical of the entire population); through
systematic errors, introduced by faulty measurements
made by personnel or due to defective equipment
that has not been calibrated; because the distribution
of data is asymmetrical or skewed; and by observer
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variation—intra- and inter-observer error can be reduced
by using the same assessor and equipment throughout
the study.
Intra-observer variation can be lowered by improv-
ing motivation, training staff, eliminating personal
biased and pragmatic views, and numerical preferences
(eg a dislike of the number ‘4’).27,28 Inter-observer
variation can be problematic, particularly in multicentre
large-scale studies when the same assessor cannot
be deployed to assess the entire patient cohort. For
instance, the assessment of test and control groups of
patients in a therapeutic study by different investi-
gators could potentially introduce fundamental inter-
observer errors into a study that will completely
invalidate the data. Reduction of inter-observer errors
can be achieved by appointing an assessment panel or
reference laboratory, or by appointing a well-trained
and qualified, enthusiastic assessor to the research team
who makes all assessments. Multicentre studies need
more logistic planning for this purpose and usually
require attendance at qualifying training courses by
the prospective assessors.27,28
Measurement of outcome parameters
Most properly designed clinical trials have one principal
outcome and several secondary outcome measures,
which are all clearly defined before the study begins.16
The use of one single principal outcome measures is
recommended, as this increases the possibility of
reaching a definite conclusion. Outcome measures
usually relate to one of three things—namely, efficacy,
safety, and quality of life issues.20
Documentation
Well-designed, pre-printed, and pre-bound clinical
record forms must be custom-made for each study.
Clinical record forms help minimise errors and varia-
bility and should be concise, instructive, and well
organised. The response to questions on the clinical
record forms (ie information entered) should be short
and precise.16 In the West, clinical record forms are
made in triplicate with the sponsor, investigator, and
archive holding one copy each. Subject compliance to
the treatment protocol must also be assessed and
documented in the clinical record forms.
Verification of data validity: monitoring
Monitors are appointed by the sponsor to independently
oversee the progress of a trial. The monitors should
ensure that the study is conducted, recorded, and
reported in accordance with the protocol and GCP.29
Trial monitoring is the single most important part of
GCP and is essential for assuring data validity and
reliability. The appointment of an independent and
knowledgeable monitor should not worry an honest
investigator whose task is actually being  facilitated.
The deployment of monitors to verify the validity of
clinical data in therapeutic trials, despite its acknow-
ledged importance and universal application in North
America and western Europe, is still not widely
practised locally. But it is anticipated that monitoring
will become increasingly more frequent as the conduct
of clinical trials becomes more sophisticated in Hong
Kong and the rest of Asia.
Analysis of data and drawing of conclusions
Only an experienced and qualified biostatistician
should analyse the clinical trial data. In many instances,
there is difficulty in documenting a treatment difference
statistically (ie type II error) due to small sample size.16
Hence it is unethical to conduct a clinical trial using
an inadequate sample size as the results will be incon-
clusive anyway. The patients and staff therefore
undergo a meaningless exercise that has potential
risks for all parties. To calculate the sample size, the
biostatistician needs to know the study design, principal
outcome measure, type of statistical tests to be used,
the smallest treatment difference in outcome measure
that can be documented as statistically different, and
α (0.05) and β (0.10 or 0.20) values.9
In addition, it is also possible to not inform the
statistician of the treatment grouping so that the
statistician cannot analyse the data in a biased manner.
This ‘triple blinding’ can also include the principal
investigator so that the risks of producing biased
conclusions are reduced.
The personnel involved in a clinical trial
The team of professionals and test subjects (patients)
have to cooperate smoothly to ensure that a successful
clinical trial is conducted (Box 3). The individuals
involved include subjects, sponsor, principal investi-
gator, monitor, Ethics Committee, supplier of trial
medications or instruments, contract research organi-
sation, and statistician.
Patients or trial subjects
Patients should be recruited after giving written
informed consent in a manner approved by the insti-
tution’s Ethics Committee. It must be stressed that
patients have no moral, clinical, or legal obligation to
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participate in any study. Patients must be reassured that
withdrawal at any stage of the study is possible without
the need to give any formal explanation and without
affecting their subsequent treatment. Financial gain by
a patient due to their participation in a trial is highly
undesirable and unethical. The safety and comfort of the
subject is of paramount importance to them and direct
out-of-hours access to the principal investigator or his
deputy must be made available. Concise but essential
information about the study and its potential implications
for an unexpected emergency should be clearly stated
on a card given to the patient which they should carry.
Cooperation is usually only gained after a friendly and
honest relationship has been established by the investi-
gator. Cooperation leads to compliance with the treatment
protocol—an absolute necessity for the smooth running
of any study. Violation of protocol ends in withdrawal of
the patient and delays the progress of a study.
The principal investigator
The principal investigator should have support from a
team of doctors, nurses, and other research personnel.
The principal investigator usually delegates the day-
to-day running of the study to a sub-investigator.
Prior to beginning the study, the principal investigator
must obtain Ethics Committee approval for the study
protocol. A sub-investigator needs to be closely super-
vised, suitably qualified, and familiar with the GCP
guidelines.12-14 The sub-investigator can be a research
assistant, nurse, research fellow or specialist trainee.
The principal investigator must ensure that whenever
appropriate, data are collected by the same support staff,
to minimise inter-observer error. In addition, adequate
training of the sub-investigator must be given so that the
intra-observer bias is also reduced.
The sponsor
The sponsor is usually an organisation and is respon-
sible for initiating, managing, and financing the study.
The sponsor is usually in charge of designing the
clinical trial, recruiting staff, and consulting with
appropriate experts. Such experts typically include
academic clinicians, clinical specialists, pharmacologists,
pharmaceutical physicians, statisticians, lawyers,
technicians, suppliers, and printers.
The sponsor should recruit qualified and respected
investigators.30 The sponsor should establish an indepen-
dent data-monitoring committee to assess the progress,
safety, efficacy end-points, and termination point of the
study. Before signing the official agreement with the
investigator, the sponsor should provide an updated
Box 3. The responsibilities of key clinical trials personnel
Personnel Responsibility
Principal investigator • must ensure that adequate time and resources are available and that appropriate
patients are selected
• obtain permission from the hospital and Ethics Committee, and obtain patient consent
• respect patient confidentiality and manage the trial code without unnecessarily breaking
the code
• dispense, retrieve unused medicines, and maintain and complete research documents
• properly collect, record, and report all data and supply these to the sponsor and monitor
• report all adverse events and observe the following regarding each patient’s care:
(1) ensure provision of resuscitation
(2) maintain medical care after the study and follow up incidental or study-related
abnormalities
(3) provide contact telephone number and a card for the attention of emergency
medical personnel
(4) maintain good clinical records and ensure that the usual medical attendant is
agreeable to the patient’s participation
Sponsor • must provide insurance or indemnity and adequate resources to perform the study
• maintain quality assurance and ensure that data are generated, documented, and
reported as per GCP guidelines
• provide the trial medications
• alert the investigators to any new findings
• handle adverse events, particularly serious ones
Subject • patients have no moral or legal responsibility to undertake a trial
• cooperation is therefore only gained by developing a good doctor-patient relationship
Monitor • verify the investigators’ qualifications, resources, technical capabilities, and supporting
staff (eg sub-investigator)
• verify the source document and other trial records and inform both the investigator and
sponsor
• report adverse events
• provide written reports to the sponsor after each site visit
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protocol and investigator’s brochure. Sufficient data
should be provided on the safety and efficacy of a drug,
with specific reference to human studies, including route
of administration, dosages, and duration of treatment.
The monitor
Monitors are appointed by the sponsor to oversee the
progress of a trial.31 They should ensure that the study
is conducted, recorded, and reported in accordance with
the protocol and GCP. Trial monitoring is the single
most important part of GCP requirement and is
essential to ensure data validity and reliability.
The Ethics Committee
A clinical trial must be accepted and monitored by
the institution’s Ethics Committee.26 This should be an
independent body comprising medical, scientific, and lay
members, whose responsibility is to protect the rights,
safety, and well-being of people involved in a clinical
trial. The committee reviews all research protocols,
consent forms, and suitability of the investigators.
Contract research organisations
Contract research organisations (CROs) are organised
institutions (academic, commercial, or both) that act on
behalf of a contracted sponsor to perform part or all of a
clinical study; CROs usually have in-house capabilities
for the design, recruiting of investigators, assurance of
quality, monitoring, and construction of the final report.
Many CROs are associated with university clinical units
to facilitate the recruitment of patients and investigators.
As they are essentially profit-making institutions, the cost
of engaging the services of a CRO is usually substantial.
The ultimate legal and moral responsibility for data
accuracy and ethics must, however, rest with the sponsor.
Clinical trials conducted by CROs are still rare in Hong
Kong but a few major international CROs have recently
established bases in south-east Asia.
Suppliers
These are usually in-house suppliers for the sponsor,
especially if the latter is a pharmaceutical company. In
studies that compare the efficacy of two drugs, however,
there might be a need to obtain the other treatment arm
from a rival pharmaceutical company. Some special
measurements need special machines that have to be
custom-made and maintained. The investigator must be
absolutely certain that the trial and placebo medications
are of the desired quality.
Statistician
The ICH GCP guidelines make it a necessity that an
expert biostatistician be actively involved in the
design and analysis of a clinical trial.12-14 In addition,
all clinical trial investigators should also have some
basic knowledge of biostatistics.
Classical ‘catches’ in clinical trials
A number of conceptual errors, which are usually not
deliberate, can arise in the administration of clinical
trials. These are as follows: a biased principal investi-
gator who designed a protocol with biased views; non-
adherence to recruitment, assessment, or the treatment
protocol; the priming of patients (‘are you feeling better
with the treatment?’); performing overanalysis of
limited data other than the predetermined primary and
secondary outcome measurements; and a change of
assessor, equipment, or methodology during the study.
The local situation
Many well-designed studies are being conducted
locally by academics as well as clinicians at various
institutes. However, many of these, including therapeutic
studies performed in collaboration with pharmaceutical
companies, are not adequately funded. This means that
the principal investigators and their affiliated personnel
have to devote enormous efforts to many aspects of
the studies that could be performed by a sub-investigator
such as a research assistant. While the design of a
study is frequently scientific and solid, there are still
many studies that lack important elements such as
randomisation, sample size calculation, and some form
of blinding. Adequate data extraction is often achieved
eventually, although the clinical data might not be
documented in carefully-designed, answer-prompting,
study-stage specific, and bound clinical record sheets.
Analysis of data is usually performed by the principal
investigators, who have some training in biostatistics,
but this can be further improved if specialist clinical
biostatisticians are consulted. Fortunately, the relative
lack of availability of the latter in Hong Kong and the
surrounding region is now improving, particularly at
the two medical faculties in Hong Kong. Although the
GCP guidelines specifically stipulate the need for data
monitoring and verification, the practice of monitoring
is still rare in Hong Kong. The situation might improve
in the near future as local training courses have recently
become available.
Despite the above local constraints and particularly,
the lack of adequate funding and professional monitors,
good-quality clinical trials can still be performed ade-
quately by local investigators. The local situation should
not bar principal investigators from designing a solid
study—this requires examination of the background
knowledge, inclusion of an adequate control group,
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recognition of the need for prospective data, and careful
construction of a detailed protocol. Lack of resources
should not discourage investigators from properly
defining outcome measures, recruiting subjects, and
designing clinical record sheets that are user-friendly and
unambiguous. The lack of monitoring, data verification,
and funding in many studies can only be improved when
pharmaceutical companies recognise that these are
essential elements of the GCP and therefore important
to the generation of ethical and solid data. Investigators
should reiterate this to their pharmaceutical counterparts
so that a culture of GCP and adequate funding can be
generated locally.
Conclusion
The gold standard therapeutic trial is a ‘randomised,
double-blind, placebo-controlled study with data
monitoring and prestudy sample size calculation’. In a
GCP-approved clinical therapeutic trial, it is typical that
the principal investigator, independent statistician, and
the sponsor have refined the study protocol and ensured
that the study’s projected end-points are scientifically
worthy and measurably sensitive. The protocol should
be approved by the institutional Ethics Committee, which
should also scrutinise the contents of the patient consent
form. The monitor and sponsor should independently
verify the expertise, availability of target patients, and
equipment claimed by the principal investigator before
the study commences. The monitor should visit the site
regularly to verify data validity by directly referring to
the source documents (eg patient’s clinical notes and
original test reports). On completion of the study, the data
should be sent to the independent expert biostatistician
for analysis, ideally with blinding of the treatment
protocol. The principal investigator can then summarise
the results and draw the relevant conclusions. The source
documents may have to be archived for many years after
completion of the study, before disposal can be permitted.
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